| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8789751 | Surgical Oncology | 2018 | 6 Pages |
Abstract
Our study suggests that the benefit of adjunctive Rx is restricted to pancreatic head tumors; body and tail tumors have a much better prognosis. These results warrant further evaluation in prospective studies.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Davendra P.S. Sohal, Katherine Tullio, Alok A. Khorana,